Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | May 2015 |
| End Date: | May 2016 |
This study evaluates the performance of a blood test for detecting biomarkers in metastatic
breast cancer patients at one clinic against standard testing.
breast cancer patients at one clinic against standard testing.
The primary objective of this pilot study is to detect the expression of FGFR1 and AR on
circulating tumor cells (CTCs) isolated from the peripheral blood of metastatic breast
cancer (MBC) patients using the OncoCEE™ platform. No procedures will be associated with
this study, as these mutations will be evaluated from the leftover blood that has already
been sent for standard of care ER and HER2 using the same platform. Results from this
testing will be correlated with results obtained from standard testing to calculate the rate
of concordance between tests.
circulating tumor cells (CTCs) isolated from the peripheral blood of metastatic breast
cancer (MBC) patients using the OncoCEE™ platform. No procedures will be associated with
this study, as these mutations will be evaluated from the leftover blood that has already
been sent for standard of care ER and HER2 using the same platform. Results from this
testing will be correlated with results obtained from standard testing to calculate the rate
of concordance between tests.
Inclusion Criteria:
- Current patient at participating clinic
- Metastatic breast cancer diagnosis
- 18 years of age or older
Exclusion Criteria:
We found this trial at
1
site
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials
